Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Invivyd reported Q2 2026 net product revenue of $14.3 million, up 21% from the prior year, while narrowing its net loss to $44.4 million despite increased clinical trial investments. The company achieved key clinical milestones, completing enrollment in the pivotal DECLARATION Phase 3 trial and fully dosing the LIBERTY Phase 3 trial for VYD2311, with top-line data from both studies anticipated in late Q3 2026.
Key figures
- Revenue
- 14300000
- Revenue Yoy
- 21%
- Rd expenses
- 29400000
- Sga expenses
- 29500000
- Cash position
- 160100000
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.